Get answers to your multiple myeloma questions. Ask Dr. Ashraf Badros.
Note: This is for informational purposes only. Our doctors cannot provide a diagnosis via e-mail.
Ashraf Badros, M.D. leads the multiple myeloma treatment team at UMGCC. He has extensive clinical experience in bone marrow transplantation with special interest in multiple myeloma. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma.
Dr. Badros research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts.
Dr. Badros is involved in the development of targeted novel therapeutics. He has completed a gene therapy trial using G-3039 "Bcl-antisense." He evaluated the use of the proteosome inhibitor "bortezomib" in the newly diagnosed myeloma patients and evaluated the effects of bortezomib on stem cell. Currently, Dr. Badros is evaluating various combinations of novel therapies in multiple myeloma such as Lenalidomide and histone deacetylase inhibitors (SAHA) in relapsed myeloma patients alone and in combinations with dexamethasone and/or bortezomib.
Vitamin D Deficiency in Patients with Multiple Myeloma
Dr. Badros's latest research (reported at the 11th International Myeloma Workshop in Kos, Greece, June, 2007) describes the first report of vitamin D deficiency and secondary hyperparathyroidism in multiple myeloma patients.
"This is practically important today as the use of bisphosphonates is limited to two years, due to side effects with prolonged use. We recommend that patients should have vitamin D levels checked and supplementation instituted to correct any deficiencies. We emphasize the need for higher daily supplementation of 1000 IU of vitamin D, rather than the standard recommendation for 400 IU daily dose. The study also addressed the role of bone turnover markers in patients receiving bisphosphonates and its implications for patients who developed osteonecrosis of the jaw," says Dr. Badros.